Ovid Therapeutics Inc.
OVID
$2.42
$0.062.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1,199.64% | 1,181.27% | 945.89% | 1,070.95% | 15.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,199.64% | 1,181.27% | 945.89% | 1,070.95% | 15.61% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1,199.64% | 1,181.27% | 945.89% | 1,070.95% | 15.61% |
| SG&A Expenses | 11.78% | -1.60% | -25.34% | -33.06% | -19.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.55% | -19.06% | -33.98% | -31.63% | -7.41% |
| Operating Income | 12.60% | 30.36% | 43.14% | 41.05% | 7.60% |
| Income Before Tax | 3.23% | 34.12% | -11.78% | -28.34% | 50.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.23% | 34.12% | -11.78% | -28.34% | 50.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.23% | 34.12% | -11.78% | -28.34% | 50.72% |
| EBIT | 12.60% | 30.36% | 43.14% | 41.05% | 7.60% |
| EBITDA | 11.91% | 30.10% | 43.25% | 41.41% | 7.77% |
| EPS Basic | 30.69% | 30.61% | -11.75% | -28.50% | 51.07% |
| Normalized Basic EPS | -51.79% | -36.38% | 10.46% | -2.21% | 56.54% |
| EPS Diluted | 30.69% | 30.61% | -10.59% | -26.83% | 51.72% |
| Normalized Diluted EPS | -51.65% | -36.27% | 10.52% | -2.15% | 56.50% |
| Average Basic Shares Outstanding | 26.81% | 3.99% | 0.35% | 0.42% | 0.49% |
| Average Diluted Shares Outstanding | 26.68% | 3.89% | 0.25% | 0.32% | 0.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |